Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer PS, Buchsbaum MS, Mantil JC.  Measuring
dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release
during a spatial attention task.  Neuroimage. 2006 May 15;31(1):139-52.

Lukic AS, Wernick MN, Strother SC.  An evaluation of methods for detecting brain activations from
functional neuroimages.  Artif Intell Med.  2002 May;25(1):69-88.

Matthews D, Mosconi M, Andrews R, Rickert K, Tsui WH, Li Yi, Mistur R, de Leon M, and the Alzheimer’s
Disease Neuroimaging Initiative.  Regional Cerebral Glucose Metabolism at Baseline Predicts Symptom
Onset in Normal ADNI Subjects and Correlates to Disease Progression.  Abstract, presented at ADNI
Investigators Meeting April, 2009.

Matthews D, Mosconi M, Andrews R, Brown T, Rickert K, Tsui WH, Li Yi, Mistur R, de Leon M, and the
Alzheimer’s Disease Neuroimaging Initiative. Combining Amyloid Imaging and Measurement of
Regional Cerebral Glucose Metabolism to Evaluate Dementia State and Progression.  Abstract,
presented at Human Amyloid Imaging Meeting, April 2009.

Matthews D, Mosconi M, Andrews R, Rickert K, Tsui WH, Li Yi, de Leon M, and the Alzheimer’s Disease
Neuroimaging Initiative.  Hippocampal Glucose Metabolism Predicts Cognitive Decline and Correlates to
Disease Progression in the ADNI Population.  Abstract, presented at the International Conference on
Alzheimer's Disease (ICAD), July 2009.

Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E,
Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S,
de Leon MJ. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's
disease, and other dementias. J Nucl Med. 2008 Mar;49(3):390-8.

Mosconi L et al.  Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image
analysis.  Neurology. 2005, Jun 14:64(11):1860-7.

Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J.  Evaluation of dopamine D-2 receptor
occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain
using 18F-fallypride. Neuropsychopharmacology. 2001 Oct;25(4):476-88.

Rusinek H, Endo Y, De Santi S, Frid D, Tsui WH, Segal S, Convit A, de Leon MJ.  Atrophy rate in medial
temporal lobe during progression of Alzheimer disease.  Neurology. 2004 Dec 28;63(12):2354-9.

Schmidt M, Mannaert E, Laruelle M, Andrews R, Brown T, Steckler T.  Standardization of 11C-raclopride
PET imaging protocols for clinical trials for the pharmaceutical industry.  Poster presented at World
Molecular Imaging Conference (WMIC), September 2008.

Strother SC, Anderson J, Hansen LK, Kjems U, Kustra R, Sidtis J, Frutiger S, Muley S, LaConte S,
Rottenberg D.  The quantitative evaluation of functional neuroimaging experiments: the NPAIRS data
analysis framework.  Neuroimage.  2002 Apr;15(4):747-71.
Copyright 2006-2010 Abiant, Inc.
References
Abiant, Inc.  480 West Center Street, Suite 202, Grayslake, Illinois  60030
Drug Evaluation...